The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
LAS VEGAS , June 26, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham...
LAS VEGAS, June 25, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary, ALT5 Sigm...
LAS VEGAS , June 13, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, released today its wholly-owned subsidiary, ALT5 Sigma, tr...
LAS VEGAS , June 11, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary, ALT5 Sig...
LAS VEGAS , June 3, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that it has been added to the Russell Micro...
LAS VEGAS, May 28, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) a multidisciplinary organization with a focus on healthcare and fintech, announced today that its Fintech subsidiary, ALT 5 Sigma,...
LAS VEGAS , May 16, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) announced today it has closed its previously announced acquisition of blockchain financial technology provider, ALT 5 Sigma Inc., an...
LAS VEGAS, March 15, 2024 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, today announ...
JanOne (NASDAQ: JAN ) stock is on the rise Thursday despite a lack of news from the clinical-stage biopharmaceutical company. There haven't been any news press releases of filings with the Securities...